A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers

被引：1

作者：

Hamerton, Leanne ^{[1
]}

Gomes, Kelly ^{[1
]}

Fougeray, Ronan ^{[2
]}

Hook, Emma S. ^{[3
]}

Gomes, Marta Vargas ^{[4
]}

Hauch, Ole ^{[4
]}

Bullement, Ash ^{[3
]}

机构：

[1] Servier Labs Ltd, Sefton House,Sefton Pk,Bells Hill, Slough SL2 4JS, Berks, England

[2] Inst Rech Int Servier, F-92210 Suresnes, France

[3] Delta Hat Ltd, Nottingham NG10 3SX, England

[4] Labs Servier, F-92150 Suresnes, France

来源：

FUTURE ONCOLOGY | 2022年 / 19卷 / 09期

关键词：

chemotherapy; cost-effectiveness analysis; gastrointestinal; esophageal; health economics; health technology assessment; Scotland; trifluridine; tipiracil; QLQ-C30; TRIAL; LIFE;

D O I：

10.2217/fon-2022-0662

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The current work was designed to estimate the cost-effectiveness of trifluridine/tipiracil (T/T) versus best supportive care (BSC) for patients with advanced stage or metastatic gastroesophageal cancer (mGC) from a UK perspective. Materials & methods: A partitioned survival analysis was undertaken using data from the phase III TAGS trial. A jointly fitted lognormal model was selected for overall survival and individual generalized gamma models were chosen for progression-free survival and time-to-treatment-discontinuation. The primary outcome was the cost per quality-adjusted life year (QALY) gained. Sensitivity analyses were undertaken to investigate uncertainty. Results: Compared with BSC, T/T was associated with a cost per QALY gained of pound 37,907. Conclusion: T/T provides a cost-effective treatment option for mGC in the UK setting.

引用

页码：643 / 650

页数：8

共 27 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
AARONSON, NK
AHMEDZAI, S
BERGMAN, B
BULLINGER, M
CULL, A
DUEZ, NJ
FILIBERTI, A
FLECHTNER, H
FLEISHMAN, SB
DEHAES, JCJM
KAASA, S
KLEE, M
OSOBA, D
RAZAVI, D
ROFE, PB
SCHRAUB, S
SNEEUW, K
SULLIVAN, M
TAKEDA, F
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
[2] [Anonymous], 2016, SUMMARY OF PRODUCT CHARACTERISTICS - Comfortis chewable tablets for dogs and cats
[3] [Anonymous], 2019, ADVISORY BOARD M MIN
[4] [Anonymous], 2021, MED ADVICE AUTOLOGOU
[5] [Anonymous], 2016, TA378 RAMUCIRUMAB TR
[6] [Anonymous], 2021, MED ADVICE TRIFLURID, P1
[7] Bray F., 2018, CA CANC J CLIN, V68, P394, DOI [DOI 10.3322/caac.20115, DOI 10.3322/CANJCLIN.49.1.33]
[8] A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments
Bullement, Ash
Cranmer, Holly L.
Shields, Gemma E.
[J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 771 - 780
[9] Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales
Bullement, Ash
Underhill, Stuart
Fougeray, Ronan
Hatswell, Anthony James
[J]. CLINICAL COLORECTAL CANCER, 2018, 17 (01) : E143 - E151
[10] Curtis L., 2018, UNIT COSTS HLTH SOCI, P1, DOI DOI 10.22024/UNIKENT/01.02.70995

← 1 2 3 →